HC Wainwright began coverage on shares of Surrozen (NASDAQ:SRZN – Free Report) in a report issued on Thursday, Marketbeat Ratings reports. The firm issued a buy rating and a $32.00 price target on the ...

Investment analysts at HC Wainwright cut their Q1 2025 earnings estimates for shares of Nurix Therapeutics in a research report issued on Wednesday, January 29th. HC Wainwright analyst R. Burns now ...

H.C. Wainwright adjusted its financial outlook for PepGen Inc. (NASDAQ:PEPG), reducing the price target to $16.00 from the ...

McEwen Mining (NYSE:MUX – Free Report) (TSE:MUX) had its price target trimmed by HC Wainwright from $19.00 to $18.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage ...

H.C. Wainwright adjusted its price target for McEwen Mining (NYSE:MUX) shares, reducing it to $18.00 from the previous $19.00 ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price objective raised by HC Wainwright from $535.00 to $550.00 in a research note released on Friday,Benzinga reports. HC Wainwright ...

H.C. Wainwright lowered the firm’s price target on PepGen (PEPG) to $16 from $26 and keeps a Buy rating on the shares after the company shared ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Mind Medicine (MNMD – Research Report) today and set a price target of ...

H.C. Wainwright initiated coverage of MetaVia (MTVA) with a Buy rating and $12 price target The company’s DA-1726 is a novel oxyntomodulin analogue designed as a dual agonist targeting glucagon ...